Next Article in Journal
Protective Effects of Lycium barbarum Polysaccharide on 6-OHDA-Induced Apoptosis in PC12 Cells through the ROS-NO Pathway
Next Article in Special Issue
Inhibition of the NF-κB Signaling Pathway by a Novel Heterocyclic Curcumin Analogue
Previous Article in Journal
Phenolic Profile of Potentilla anserina L. (Rosaceae) Herb of Siberian Origin and Development of a Rapid Method for Simultaneous Determination of Major Phenolics in P. anserina Pharmaceutical Products by Microcolumn RP-HPLC-UV
Previous Article in Special Issue
Curcumin Differs from Tetrahydrocurcumin for Molecular Targets, Signaling Pathways and Cellular Responses
Open AccessReview

Eliminating the Heart from the Curcumin Molecule: Monocarbonyl Curcumin Mimics (MACs)

1
Center for Self–assembly and Complexity, Institute for Basic Science, Pohang 790-784, Korea
2
Department of Chemistry, Emory University, Atlanta, GA 30322, USA
3
Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA 30322, USA
4
Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Bharat B. Aggarwal and Sahdeo Prasad
Molecules 2015, 20(1), 249-292; https://doi.org/10.3390/molecules20010249
Received: 29 October 2014 / Accepted: 10 December 2014 / Published: 24 December 2014
(This article belongs to the Special Issue Curcumin, Inflammation, and Chronic Diseases: How are They Linked?)
Curcumin is a natural product with several thousand years of heritage. Its traditional Asian application to human ailments has been subjected in recent decades to worldwide pharmacological, biochemical and clinical investigations. Curcumin’s Achilles heel lies in its poor aqueous solubility and rapid degradation at pH ~ 7.4. Researchers have sought to unlock curcumin’s assets by chemical manipulation. One class of molecules under scrutiny are the monocarbonyl analogs of curcumin (MACs). A thousand plus such agents have been created and tested primarily against cancer and inflammation. The outcome is clear. In vitro, MACs furnish a 10–20 fold potency gain vs. curcumin for numerous cancer cell lines and cellular proteins. Similarly, MACs have successfully demonstrated better pharmacokinetic (PK) profiles in mice and greater tumor regression in cancer xenografts in vivo than curcumin. The compounds reveal limited toxicity as measured by murine weight gain and histopathological assessment. To our knowledge, MAC members have not yet been monitored in larger animals or humans. However, Phase 1 clinical trials are certainly on the horizon. The present review focuses on the large and evolving body of work in cancer and inflammation, but also covers MAC structural diversity and early discovery for treatment of bacteria, tuberculosis, Alzheimer’s disease and malaria. View Full-Text
Keywords: monocarbonyl analogs of curcumin; MACs; inflammation; cancer; infectious disease; anti-angiogenesis; NF-κB; TNF-α monocarbonyl analogs of curcumin; MACs; inflammation; cancer; infectious disease; anti-angiogenesis; NF-κB; TNF-α
Show Figures

Graphical abstract

MDPI and ACS Style

Shetty, D.; Kim, Y.J.; Shim, H.; Snyder, J.P. Eliminating the Heart from the Curcumin Molecule: Monocarbonyl Curcumin Mimics (MACs). Molecules 2015, 20, 249-292.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop